Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Raised to $55.00

Amylyx Pharmaceuticals (NASDAQ:AMLX) had its price target boosted by HC Wainwright from $34.00 to $55.00 in a research report sent to investors on Tuesday, Marketbeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ FY2028 earnings at ($0.97) EPS, FY2029 earnings at $3.22 EPS and FY2030 earnings at $6.40 EPS.

Other analysts also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday, August 5th. Guggenheim increased their price target on Amylyx Pharmaceuticals from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, June 25th. Citigroup raised their price objective on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Mizuho boosted their price objective on Amylyx Pharmaceuticals from $24.00 to $30.00 and gave the company an “outperform” rating in a report on Monday. Finally, Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $36.25.

Amylyx Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ AMLX opened at $39.66 on Tuesday. The firm has a market cap of $4.42 billion, a PE ratio of -27.73 and a beta of -0.21. The company’s fifty day simple moving average is $19.89 and its 200 day simple moving average is $16.53. Amylyx Pharmaceuticals has a 12-month low of $7.96 and a 12-month high of $40.44.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.03). On average, equities analysts predict that Amylyx Pharmaceuticals will post -1.48 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This trade represents a 7.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Landscape Capital Management L.L.C. grew its position in shares of Amylyx Pharmaceuticals by 17.5% during the 4th quarter. Landscape Capital Management L.L.C. now owns 12,226 shares of the company’s stock valued at $148,000 after acquiring an additional 1,825 shares during the period. KBC Group NV bought a new stake in shares of Amylyx Pharmaceuticals in the 1st quarter worth approximately $26,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Amylyx Pharmaceuticals by 54.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,337 shares of the company’s stock valued at $64,000 after purchasing an additional 1,890 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Amylyx Pharmaceuticals in the fourth quarter valued at approximately $25,000. Finally, State of Wyoming purchased a new position in Amylyx Pharmaceuticals in the second quarter valued at approximately $40,000. 95.84% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: Avexitide reduced hypoglycemic events by 55% in the pivotal Phase 3 LUCIDITY study for post-bariatric hypoglycemia. Amylyx is preparing for additional data and expects to pursue a potential FDA filing by the end of 2026, strengthening the drug’s commercialization outlook. AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
• Positive Sentiment: Analysts raised their valuations following the clinical success. Guggenheim increased its price target to $55 from $40, while Robert W. Baird lifted its target to $52 from $28. Wolfe Research also upgraded Amylyx to “strong buy.”
• Positive Sentiment: HC Wainwright raised its long-term EPS forecasts to $3.22 for fiscal 2029 and $6.40 for fiscal 2030, compared with prior estimates of $1.66 and $3.74, respectively. The firm maintained a “Buy” rating and a $55 price target, reflecting expectations for substantial future revenue from avexitide. Amylyx Sets New 52-Week High After Analyst Upgrade
• Neutral Sentiment: The stock reached a new 52-week high amid heavy trading, showing strong momentum but also increasing the risk of volatility after its sharp recent advance.
• Negative Sentiment: Amylyx priced an upsized public offering of 14.09 million shares at $35.50 each, expected to raise approximately $500 million before expenses. Underwriters may purchase another 2.11 million shares, creating potential dilution for existing shareholders. The proceeds should improve the company’s financial resources, but the offering price below recent trading levels may pressure the stock. Amylyx Announces Pricing of an Upsized $500 Million Public Offering

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on therapies intended to protect nerve cells and address the underlying biology of conditions such as amyotrophic lateral sclerosis (ALS) and other serious neurological disorders.

Amylyx’s lead product, AMX0035, was marketed in the United States as Relyvrio and in Canada as Albrioza for the treatment of ALS. Following results from a confirmatory clinical trial that did not meet its objectives, the company announced the voluntary withdrawal of the product from the market in 2024.